Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel

LUND, Sweden and PETACH TIKVA, IsraelDec. 7, 2021 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies to patients in international markets ("Medison"), today announce a multiregional agreement for Medison to commercialize Hansa's desensitization treatment for kidney transplants in Central Eastern Europe and Israel. The commercialization is based on current conditional marketing authorization for the EU and the UK, and pending marketing authorization by Israel's Ministry of Health. A respective application for marketing authoritization for desensitization treatment in kidney transplant was filed in Israel earlier this year and, if granted, will make Israel the first market outside of Europe where imlifidase is commercialized. Hansa and Medison will be working together to obtain pricing and reimbursement as required depending on the country.

The partnership covers the following countries within the Central Eastern European region: CroatiaHungaryPoland and Slovenia in addition to Israel.

"This new commercial partnership with Medison Pharma is an important milestone for Hansa as it expands access to imlifidase for highly sensitized patients awaiting kidney transplants," says Søren Tulstrup, President & CEO of Hansa. "Patients with this rare condition currently face long wait times or are unable to find a suitable donor match, due to high levels of preformed antibodies elevating the risk of rejection."

"We are delighted to partner with Hansa Biopharma to accelerate the reach of this novel treatment for kidney disease", says Meir Jakobsohn, Founder and CEO of Medison Pharma. "In our joint commitment to address the unmet medical needs of patients with rare conditions, we look forward to leveraging our commercial platform and providing patients  in international markets with access to this much needed therapy."

For the complete press release: www.prnewswire.com